{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ahmed M. Hamdy M.D.", "age": 59, "title": "Co-Founder & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 657537, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Dr. Raquel E. Izumi Ph.D.", "age": 54, "title": "Co-Founder, Acting CEO, Secretary & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 591540, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Mr. Tom C. Thomas J.D.", "age": 64, "title": "Founder, General Counsel & Chief Legal Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 444142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Byrd M.D.", "title": "Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Haas", "age": 59, "title": "Acting CFO, VP of Finance & Corporate Controller", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Lerchen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabriela  Jairala", "title": "VP of Investor Relations & Corporate Communications and Chief of Staff", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Quarford M.B.A.", "title": "Vice President of Quality Operations & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Merrick SPHR", "title": "Senior Director of People & Culture and Head of Human Resource", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Beatrix  Stelte-Ludwig Ph.D.", "title": "Executive Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.5294, "open": 0.5135, "dayLow": 0.5135, "dayHigh": 0.575, "regularMarketPreviousClose": 0.5294, "regularMarketOpen": 0.5135, "regularMarketDayLow": 0.5135, "regularMarketDayHigh": 0.575, "payoutRatio": 0.0, "beta": 1.166, "forwardPE": -0.8582089, "volume": 216822, "regularMarketVolume": 216822, "averageVolume": 1013269, "averageVolume10days": 381580, "averageDailyVolume10Day": 381580, "bid": 0.5497, "ask": 0.5861, "bidSize": 3, "askSize": 3, "marketCap": 3009711, "fiftyTwoWeekLow": 0.484, "fiftyTwoWeekHigh": 136.8, "fiftyDayAverage": 1.16474, "twoHundredDayAverage": 7.701185, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -7496361, "profitMargins": 0.0, "floatShares": 1535300, "sharesOutstanding": 2239580, "sharesShort": 68814, "sharesShortPriorMonth": 108516, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0307, "heldPercentInsiders": 0.115930006, "heldPercentInstitutions": 0.10769, "shortRatio": 0.19, "shortPercentOfFloat": 0.0339, "impliedSharesOutstanding": 5234280, "bookValue": 5.802, "priceToBook": 0.099103756, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -27030000, "trailingEps": -15.85, "forwardEps": -0.67, "lastSplitFactor": "1:20", "lastSplitDate": 1738022400, "enterpriseToEbitda": 0.267, "52WeekChange": -0.9956439, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.575, "targetHighPrice": 200.0, "targetLowPrice": 200.0, "targetMeanPrice": 200.0, "targetMedianPrice": 200.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 10086000, "totalCashPerShare": 6.011, "ebitda": -28119000, "totalDebt": 1639000, "quickRatio": 2.055, "currentRatio": 2.166, "debtToEquity": 17.995, "returnOnAssets": -0.8542, "returnOnEquity": -2.17554, "freeCashflow": -16435250, "operatingCashflow": -27965000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VINC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Vincerx Pharma, Inc.", "regularMarketChange": 0.045599997, "regularMarketDayRange": "0.5135 - 0.575", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1013269, "fiftyTwoWeekLowChange": 0.09099999, "fiftyTwoWeekLowChangePercent": 0.1880165, "fiftyTwoWeekRange": "0.484 - 136.8", "fiftyTwoWeekHighChange": -136.225, "fiftyTwoWeekHighChangePercent": -0.9957968, "fiftyTwoWeekChangePercent": -99.56439, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -15.85, "epsForward": -0.67, "fiftyDayAverageChange": -0.58974, "fiftyDayAverageChangePercent": -0.50632757, "twoHundredDayAverageChange": -7.1261854, "twoHundredDayAverageChangePercent": -0.9253362, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Vincera Pharma, Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "2.0 - Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1590586200000, "preMarketChange": 0.004999995, "preMarketChangePercent": 0.8695644, "preMarketPrice": 0.58, "longName": "Vincerx Pharma, Inc.", "corporateActions": [], "preMarketTime": 1743595860, "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_690173412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "regularMarketChangePercent": 8.613524, "regularMarketPrice": 0.575, "marketState": "PRE", "displayName": "Vincerx Pharma", "trailingPegRatio": null}